Drug intelligence / Profile preview

TQB6457

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TQB6457 is a Class 1 innovative biologic developed by Chia Tai Tianqing (CTTQ). It is a first-in-class fixed-dose combination formulation consisting of a CCR8 monoclonal antibody and a PD-1 monoclonal antibody. TQB6457 is designed to target advanced malignant tumors by simultaneously depleting tumor-infiltrating regulatory T cells (Tregs) via CCR8 targeting and blocking the PD-1/PD-L1 immune checkpoint pathway, thereby enhancing anti-tumor immune responses. The drug received implied clinical trial approval from China's CDE in March 2026 and is currently in Phase 1 clinical development.

Targets

CCR8PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on TQB6457.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB6457.